Cosmo Pharmaceuticals N.V. (SWX: COPN)
Switzerland
· Delayed Price · Currency is CHF
62.30
-0.20 (-0.32%)
Nov 20, 2024, 3:40 PM CET
Cosmo Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 185.36 | 92.78 | 102.09 | 65.07 | 60.95 | 62.5 | Upgrade
|
Revenue | 185.36 | 92.78 | 102.09 | 65.07 | 60.95 | 62.5 | Upgrade
|
Revenue Growth (YoY) | 77.82% | -9.12% | 56.88% | 6.77% | -2.47% | -4.76% | Upgrade
|
Cost of Revenue | 43.62 | 39.34 | 40.49 | 32.98 | 27.62 | 25.05 | Upgrade
|
Gross Profit | 141.74 | 53.44 | 61.6 | 32.1 | 33.33 | 37.44 | Upgrade
|
Selling, General & Admin | 37.31 | 30.79 | 19.98 | 10.52 | 18.68 | 35.34 | Upgrade
|
Research & Development | 20.49 | 17.95 | 15.46 | 11.29 | 13.6 | 15.16 | Upgrade
|
Other Operating Expenses | -2.04 | -1.45 | -1.9 | -0.82 | -0.75 | -0.75 | Upgrade
|
Operating Expenses | 55.76 | 47.29 | 33.54 | 21 | 31.53 | 49.75 | Upgrade
|
Operating Income | 85.98 | 6.15 | 28.06 | 11.1 | 1.81 | -12.31 | Upgrade
|
Interest Expense | -4.02 | -8.53 | -9.16 | -8.99 | -8.73 | -8.53 | Upgrade
|
Interest & Investment Income | 3.46 | 4.07 | 2.94 | 3.06 | 1.75 | 0.97 | Upgrade
|
Earnings From Equity Investments | - | - | - | 17.75 | -4.94 | -5.06 | Upgrade
|
Currency Exchange Gain (Loss) | -0.42 | -1.36 | 2.76 | 2.24 | -1.49 | 1.33 | Upgrade
|
Other Non Operating Income (Expenses) | -0.07 | -0.12 | -0.11 | -0.48 | -0.17 | -0.19 | Upgrade
|
EBT Excluding Unusual Items | 84.93 | 0.21 | 24.49 | 24.68 | -11.78 | -23.79 | Upgrade
|
Gain (Loss) on Sale of Investments | 1.68 | 1.33 | -0.02 | -0.68 | -0.25 | 2.49 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | - | - | 4 | - | Upgrade
|
Other Unusual Items | - | - | - | - | 1.1 | - | Upgrade
|
Pretax Income | 86.61 | 1.53 | 24.47 | 24 | -6.93 | -21.3 | Upgrade
|
Income Tax Expense | 16.77 | 6.26 | 6.97 | 2.33 | 0.97 | 3.19 | Upgrade
|
Earnings From Continuing Operations | 69.84 | -4.73 | 17.51 | 21.67 | -7.9 | -24.49 | Upgrade
|
Minority Interest in Earnings | -0.27 | -0.2 | -0.28 | -0 | - | 0.08 | Upgrade
|
Net Income | 69.57 | -4.93 | 17.23 | 21.67 | -7.9 | -24.42 | Upgrade
|
Net Income to Common | 69.57 | -4.93 | 17.23 | 21.67 | -7.9 | -24.42 | Upgrade
|
Net Income Growth | 541.82% | - | -20.52% | - | - | - | Upgrade
|
Shares Outstanding (Basic) | 16 | 16 | 16 | 17 | 14 | 15 | Upgrade
|
Shares Outstanding (Diluted) | 16 | 16 | 16 | 17 | 14 | 15 | Upgrade
|
Shares Change (YoY) | -0.77% | -1.95% | -2.83% | 16.81% | -1.11% | -2.48% | Upgrade
|
EPS (Basic) | 4.33 | -0.31 | 1.05 | 1.29 | -0.55 | -1.67 | Upgrade
|
EPS (Diluted) | 4.32 | -0.31 | 1.05 | 1.28 | -0.55 | -1.67 | Upgrade
|
EPS Growth | 546.83% | - | -18.20% | - | - | - | Upgrade
|
Free Cash Flow | 113.99 | 30.28 | 28.71 | 7.12 | 8.87 | -21.09 | Upgrade
|
Free Cash Flow Per Share | 7.08 | 1.88 | 1.75 | 0.42 | 0.61 | -1.44 | Upgrade
|
Dividend Per Share | 2.000 | 2.000 | 1.050 | 0.950 | - | - | Upgrade
|
Dividend Growth | 90.48% | 90.48% | 10.53% | - | - | - | Upgrade
|
Gross Margin | 76.47% | 57.60% | 60.34% | 49.32% | 54.69% | 59.91% | Upgrade
|
Operating Margin | 46.38% | 6.62% | 27.48% | 17.06% | 2.96% | -19.69% | Upgrade
|
Profit Margin | 37.53% | -5.32% | 16.87% | 33.30% | -12.96% | -39.07% | Upgrade
|
Free Cash Flow Margin | 61.50% | 32.63% | 28.12% | 10.95% | 14.54% | -33.75% | Upgrade
|
EBITDA | 99.91 | 19.7 | 41.17 | 17.81 | 6.06 | -8.54 | Upgrade
|
EBITDA Margin | 53.90% | 21.23% | 40.33% | 27.37% | 9.94% | -13.66% | Upgrade
|
D&A For EBITDA | 13.93 | 13.55 | 13.11 | 6.71 | 4.25 | 3.77 | Upgrade
|
EBIT | 85.98 | 6.15 | 28.06 | 11.1 | 1.81 | -12.31 | Upgrade
|
EBIT Margin | 46.38% | 6.62% | 27.48% | 17.06% | 2.96% | -19.69% | Upgrade
|
Effective Tax Rate | 19.36% | 408.88% | 28.47% | 9.71% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.